Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …

Fluoropyrimidines remain the cornerstone of treatment for different types of cancer, and are
used by an estimated two million patients annually. The toxicity associated with …

Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed
anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine …

Fluoropyrimidine drugs (FP) are the backbone of many chemotherapy protocols for treating
solid tumours. The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Abstract Fluoropyrimidines, including 5-fluorouracil (5-FU), are widely used in the treatment
of solid tumors and remain the backbone of many combination regimens. Despite their …

The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine,
are frequently prescribed for several types of cancer, including breast, colorectal, head and …

Fluoropyrimidines (FP; 5‐fluorouracil, capecitabine, and tegafur) are a commonly prescribed
class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 …

Fluoropyrimidines (FU) are still the most prescribed anticancer drugs for the treatment of
solid cancers. However, fluoropyrimidines cause severe toxicities in 10 to 40% of patients …

Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation
in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not …